Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 9, 2006

Source MDx Initiates RA Collaboration and Receives RA Grant

  • Tufts-New England Medical Center (NEMC) and Source MDx will collaborate to develop a molecular diagnostic test for rheumatoid arthritis. Researchers at Tufts-NEMC, led by co-principal investigator, Tim McAlindon, M.D., chief of rheumatology at Tufts-NEMC, will manage the clinical studies for a molecular diagnostic test that will characterize rheumatoid arthritis patients and their response to anti-TNF therapy.

    Source MDx will provide gene expression analysis of whole blood samples from the approximately 100 participating patient population based on its RA Precision Profile™ gene panel designed to diagnose and monitor RA patients and its Healthy Normals Reference dataset.

    In conjunction with the Tufts-NEMC study, Source MDx was awarded an SBIR grant by the NIH to initiate the development of a molecular diagnostic test using biomarkers to predict responders and non responders to antitumor neurosis factor therapy for rheumatoid arthritis. The grant provides over $195,000 in funding over a one-year period.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »